Avencell

Next generation immunotherapies for hard-to-treat cancers.

Watertown, United States · Founded 2021 · $152.0M raised

Employees
51–200
Founded
2021
Business Model
B2B
Total Funding
$152.0M
Last Round
$40.0M GrantJun 2025
Rounds
5

About

AvenCell Therapeutics is a clinical-stage biopharma developing next-generation allogeneic and switchable CAR-T cell therapies for hard-to-treat cancers. Their proprietary platforms enable precise targeting, controllability, and safety, overcoming limitations of current immunotherapies. Backed by leading investors, they focus on advancing immunotherapies to improve patient outcomes globally.

Summary

Avencell is a Biotech company based in Watertown, United States, founded in 2021. It has raised $152.0M in total across 5 rounds, most recently a $40.0M Grant round in Jun 2025. Investors include F-Prime Capital, Japanese Agency for Medical Research and Development (AMED) and Novo Holdings A/S.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

GrantAMED GrantJun 2025
$40.0M

Sign up to see all 5 rounds

Grant — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Avencell on Indexed.vc
<a href="https://indexed.vc/companies/avencell"><img src="https://indexed.vc/api/badge/company/avencell" alt="Avencell on Indexed.vc" width="260" height="76" /></a>